Lantern Pharma Inc (LTRN)

$3.38 -0.08 (-2.31%)
Market Cap 37.80M
Revenue (ttm) 0.00
Net Income (ttm) -20.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 34,200
Avg Vol 142,714
Day's Range N/A - N/A
Shares Out 11.18M
Stochastic %K 41%
Beta 1.52
Analysts Strong Sell
Price Target $25.00

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 277 1136
Address:
1920 McKinney Avenue, 7th Floor, Dallas, United States
NetworkNewsWire
NetworkNewsWire Nov. 13 at 4:21 PM
InvestorNewsBreaks – $LTRN Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress https://ibn.fm/apyOH
0 · Reply
Bulltrader988
Bulltrader988 Nov. 13 at 2:03 PM
$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-reports-third-quarter-2025-financial-results-and-fx5397jhdqpf.html
0 · Reply
MrTicker
MrTicker Nov. 13 at 12:00 PM
$LTRN Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate BENZINGA 5:03 AM ET 11/13/2025
0 · Reply
MrTicker
MrTicker Nov. 13 at 11:59 AM
$LTRN Lantern Pharma (LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the same period last year.
0 · Reply
Daddy044
Daddy044 Nov. 13 at 10:48 AM
$LTRN I am watching this one more closely. The call today will be interesting to hear. https://us06web.zoom.us/j/9177517141
0 · Reply
Daddy044
Daddy044 Nov. 12 at 11:27 PM
$LTRN Upside from here good entry point! Data
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 10 at 5:20 PM
AINewsBreaks – $LTRN CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE https://ibn.fm/ZvbMK
0 · Reply
MrTicker
MrTicker Nov. 7 at 2:00 PM
$LTRN Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows ACCESS NEWSWIRE 8:00 AM ET 11/7/2025
0 · Reply
Bulltrader988
Bulltrader988 Nov. 6 at 7:45 PM
$LTRN "..., today announced that it will host its third quarter 2025 operating and financial results webcast on Thursday, November 13, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time..." 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-to-report-third-quarter-2025-operating-financial-sq40no355zq1.html
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 6 at 5:39 PM
AINewsBreaks – $LTRN Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments https://ibn.fm/BMDrb
0 · Reply
Latest News on LTRN
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 1:11 PM EST - 3 days ago

Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 13, 2025, 8:30 AM EST - 3 days ago

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Nov 6, 2025, 8:00 AM EST - 10 days ago

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Oct 30, 2025, 8:00 AM EDT - 17 days ago

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Oct 28, 2025, 8:49 AM EDT - 19 days ago

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Oct 24, 2025, 8:00 AM EDT - 23 days ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

Sep 16, 2025, 8:29 AM EDT - 2 months ago

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Sep 10, 2025, 8:00 AM EDT - 2 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Sep 3, 2025, 9:44 AM EDT - 2 months ago

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Aug 13, 2025, 4:30 PM EDT - 3 months ago

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Aug 6, 2025, 8:30 AM EDT - 3 months ago

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Aug 4, 2025, 8:55 AM EDT - 3 months ago

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Jul 28, 2025, 8:00 AM EDT - 3 months ago

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Jul 23, 2025, 7:56 AM EDT - 4 months ago

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Jul 21, 2025, 8:20 AM EDT - 4 months ago

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Jul 15, 2025, 9:40 AM EDT - 4 months ago

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Jun 16, 2025, 8:30 AM EDT - 5 months ago

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 29, 2025, 8:30 AM EDT - 6 months ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

May 15, 2025, 3:04 PM EDT - 6 months ago

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 15, 2025, 8:45 AM EDT - 6 months ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 12, 2025, 9:00 AM EDT - 6 months ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

May 8, 2025, 8:30 AM EDT - 6 months ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

May 5, 2025, 8:55 AM EDT - 6 months ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:35 PM EDT - 8 months ago

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 8 months ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 8 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Feb 19, 2025, 8:00 AM EST - 9 months ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Jan 27, 2025, 7:55 AM EST - 10 months ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 9, 2024, 8:15 AM EST - 1 year ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Dec 3, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 26, 2024, 8:45 AM EST - 1 year ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 19, 2024, 8:00 AM EST - 1 year ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:23 PM EST - 1 year ago

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Nov 5, 2024, 8:00 AM EST - 1 year ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 23, 2024, 8:45 AM EDT - 1 year ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Oct 15, 2024, 9:07 AM EDT - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 4:01 AM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 7, 2024, 9:31 AM EDT - 1 year ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 9, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 6, 2024, 3:00 AM EDT - 1 year ago

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

NetworkNewsWire
NetworkNewsWire Nov. 13 at 4:21 PM
InvestorNewsBreaks – $LTRN Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress https://ibn.fm/apyOH
0 · Reply
Bulltrader988
Bulltrader988 Nov. 13 at 2:03 PM
$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-reports-third-quarter-2025-financial-results-and-fx5397jhdqpf.html
0 · Reply
MrTicker
MrTicker Nov. 13 at 12:00 PM
$LTRN Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate BENZINGA 5:03 AM ET 11/13/2025
0 · Reply
MrTicker
MrTicker Nov. 13 at 11:59 AM
$LTRN Lantern Pharma (LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the same period last year.
0 · Reply
Daddy044
Daddy044 Nov. 13 at 10:48 AM
$LTRN I am watching this one more closely. The call today will be interesting to hear. https://us06web.zoom.us/j/9177517141
0 · Reply
Daddy044
Daddy044 Nov. 12 at 11:27 PM
$LTRN Upside from here good entry point! Data
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 10 at 5:20 PM
AINewsBreaks – $LTRN CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE https://ibn.fm/ZvbMK
0 · Reply
MrTicker
MrTicker Nov. 7 at 2:00 PM
$LTRN Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows ACCESS NEWSWIRE 8:00 AM ET 11/7/2025
0 · Reply
Bulltrader988
Bulltrader988 Nov. 6 at 7:45 PM
$LTRN "..., today announced that it will host its third quarter 2025 operating and financial results webcast on Thursday, November 13, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time..." 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-to-report-third-quarter-2025-operating-financial-sq40no355zq1.html
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 6 at 5:39 PM
AINewsBreaks – $LTRN Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments https://ibn.fm/BMDrb
0 · Reply
mankind1
mankind1 Nov. 2 at 1:44 AM
$LTRN glad to see they'll be showcases some new things.
0 · Reply
DARKP00L
DARKP00L Oct. 30 at 12:12 PM
$LTRN 08:11 on Oct. 30 2025 Lantern Pharma To Showcase Two Of Its Commercially Deployed AI Research Platforms At The Inaugural AI For Biology And Medicine Symposium At The University Of North Texas #tradeideas
0 · Reply
MrTicker
MrTicker Oct. 30 at 12:12 PM
$LTRN Lantern Pharma To Showcase Two Of Its Commercially Deployed AI Research Platforms At The Inaugural AI For Biology And Medicine Symposium At The University Of North Texas BENZINGA 7:11 AM ET 10/30/2025
0 · Reply
Bulltrader988
Bulltrader988 Oct. 30 at 12:02 PM
$LTRN "...Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas. The symposium, hosted by Dr. Serdar Bozdag and the newly established Center for Computational Life Sciences, brings together leading researchers advancing the intersection of artificial intelligence and biomedicine...." 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-to-present-ai-driven-cancer-drug-development-research-1dxsb7jvlwv3.html
0 · Reply
MrTicker
MrTicker Oct. 30 at 12:01 PM
$LTRN Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT BUSINESS WIRE 7:00 AM ET 10/30/2025
0 · Reply
Drugtrade
Drugtrade Oct. 30 at 2:29 AM
$LTRN this did...nothing. on good news.. lost my patience twice now
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 28 at 6:18 PM
AINewsBreaks – $LTRN Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress https://ibn.fm/J08p2
0 · Reply
Bulltrader988
Bulltrader988 Oct. 28 at 1:39 PM
$LTRN 👃👀 https://www.stocktitan.net/news/LTRN/lantern-pharma-presents-lp-284-clinical-data-at-25th-ll-m-congress-2my92z6awrpg.html
0 · Reply
TurboGains69
TurboGains69 Oct. 28 at 12:55 PM
$LTRN huge news!
0 · Reply
MrTicker
MrTicker Oct. 28 at 12:50 PM
$LTRN Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. BUSINESS WIRE 7:49 AM ET 10/28/2025
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 28 at 12:50 PM
$LTRN (+3.7% pre) Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers https://ooc.bz/l/82156
0 · Reply
CasinoJackpot
CasinoJackpot Oct. 27 at 10:02 PM
Big news on ticker RELI 🚨 Bulls are all over RELI! News Getting found!! RELI gearing up for explosion, don't miss out!! RELI 🔹 Momentum surging after adding Solana (SOL) to its digital asset treasury 🚀 🔹 Momentum surging after adding Solana (SOL) to its digital asset treasury 🚀 🔹 Dividend announcement sparking renewed trader interest 💰 🔹 Micro-cap insurance play turning heads in the crypto crossover space 🔄 🔹 Low float + high volume = perfect setup for volatility 📈 $SNAL $FRGT $LTRN $ASST ..L
0 · Reply